Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: Results from a 2-year, prospective study in antipsychotic-nave patients

Neuropsychopharmacology

Volumn 36, Issue 8, 2011, Pages 1738-1746

  Woerner, Margaret G ^a   Correll, Christoph U ^a,b   Alvir, Jose Ma J ^c   Greenwald, Blaine ^a,b   Delman, Howard ^a   Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

antipsychotics; cohort study; elderly; olanzapine; risperidone; tardive dyskinesia

Indexed keywords

OLANZAPINE; RISPERIDONE;

AFRICAN AMERICAN; AGED; AGITATION; ARTICLE; COHORT ANALYSIS; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERIATRIC PATIENT; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INCIDENCE; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NURSING HOME; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; TARDIVE DYSKINESIA;

EID: 85027927321     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.55     Document Type: Article

References (40)

1. American Psychiatric Association Committee on Nomenclature and Statistics (1987). Diagnostic and Statistical Manual of Mental Disorders, DSMIV. American Psychiatric Association: Washington, DC.
2. Briesacher BA, Limcango MR, Simone-Wastila L, Doshi JA, Levens SR, Shea DG et al (2005). The quality of drug prescribing in nursing homes. Arch Intern Med 165: 1280-1285. (Pubitemid 40989593)
3. Caroff S, Mann S, Campbell ES, Sullivan KA (2002). Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63(Suppl 4): 12-19. (Pubitemid 34242106)
4. Casey DE (1999). Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Res 35: S61-S66. (Pubitemid 29133026)
5. Chakos MH, Alvir JMaJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D et al (1996). Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53: 313-319. (Pubitemid 26115304)
6. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414-425. (Pubitemid 38326094)
7. Correll CU, Kane JM (2007). One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 17: 647-656.
8. Correll CU, Schenk EM (2008). Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21: 151-156. (Pubitemid 351339869)
9. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Risperidone Working Group et al (2000). A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 15: 506-514. (Pubitemid 30409992)
10. de Leon J (2007). The effect of atypical vs typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 257: 169-172. (Pubitemid 46599131)
11. Dolder CR, Jeste DV (2003). Incidence of tardive dyskinesia with typical vs atypical antipsychotics in very high risk patients. Biol Psychiatry 53: 1142-1145. (Pubitemid 36695090)
12. Glazer WM, Morgenstern H, Doucette JT (1993). Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 54: 133-139. (Pubitemid 23141515)
13. Glazer WM, Morgenstern H, Doucette J (1994). Race and tardive dyskinesia among outpatients at a CMHC. Hosp Commun Psychiatry 45: 38-42. (Pubitemid 24026567)
14. Glazer WM, Morgenstern H, Pultz JA, Yeung PP, Rak IW (1999). Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses. In: Proceedings of the 38th Annual Meeting of the American College of Neuro-psychopharmacology. ACNP: Nashville, TN. p 271.
15. Guy W (1976). ECDEU Assessment Manual for Psychopharmacol-ogy, revised. National Institute of Mental Health: Rockville, MD. Pub. No. (ADM) 76-338. National Institute of Mental Health.
16. Jeste DV, Caliguiri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ et al (1995). Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 52: 756-765.
17. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP (1999a). Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 156: 309-311. (Pubitemid 29077124)
18. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA (2000). Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 157: 1150-1155. (Pubitemid 30432498)
19. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J (1999b). Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 7: 70-76. (Pubitemid 29029832)
20. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA (1993). Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54: 327-330. (Pubitemid 23322379)
21. Kinon BJ, Stauffer VL, Kaiser CJ, Hay DP, Kollack-Walker S (2005). Incidence of presumptive tardive dyskinesia in elderly patients treated with olanzapine or conventional antipsychotics. Poster Presented at the International Congress of Parkinson's Disease and Movement Disorders: New Orleans, Louisiana, USA. Poster no. 49.
22. Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G et al (2005). Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 53: 1374-1379. (Pubitemid 41602483)
23. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM et al (2002). The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28: 5-16. (Pubitemid 34534746)
24. Miller DD, Caroff SN, Davis SM, Rosenheck RA, Mc E, Saltz BL et al (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193: 279-288.
25. Morgenstern H, Glazer WM (1993). Identifying risk factors for tardive dyskinesia among neuroleptic medication: results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 50: 723-733. (Pubitemid 23263809)
26. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996). A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49: 1373-1379. (Pubitemid 27028925)
27. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225-235. Erratum in N Engl J Med. 2009 Oct 29;361(18):1814.
28. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ et al (1991). Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266: 2402-2406.
29. SAS Institute (1989). SAS/STAT User's Guide, version 6, Vol 2, 4th edn. SAS Institute: Cary, NC.
30. SAS Institute (1994). SAS/STAT Software: Changes and Enhancements, SAS Institute: Cary, NC.
31. Schneider LS, Dagerman KS, Insel P (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934-1943. (Pubitemid 41464695)
32. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia (RD-TD). Arch Gen Psychiatry 39: 486-487. (Pubitemid 12152819)
33. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
34. Simpson GM, Lee JH, Zoubok B, Gardos G (1979). A rating scale for tardive dyskinesia. Psychopharmacology 64: 171-179. (Pubitemid 9227085)
35. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH et al (2005). Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 353: 2335-2341. (Pubitemid 41713745)
36. Woerner MG, Alvir JMaJ, Saltz BL, Lieberman JA, Kane JM (1998). Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155: 1521-1528. (Pubitemid 28512019)
37. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663-667. (Pubitemid 36750143)
38. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R et al (2010). Incidence of tardive dyskinesia with atypical vs conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71: 463-474.
39. Yassa R, Jeste DV (1997). Gender as a factor in the development of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV (eds). Neuroleptic Induced Movement Disorder. Cambridge University Press: Cambridge, 40-56.
40. Yassa R, Nastase C, Dupont D, Thibeau M (1992). Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 149: 1206-1211.